{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:25:44Z","timestamp":1790670344423,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T00:00:00Z","timestamp":1491609600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"This study was supported by The Norwegian Research Council (FORNY program), Innovation Norway AS, Ultimovacs AS."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00262-017-1994-y","type":"journal-article","created":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T06:31:25Z","timestamp":1491633085000},"page":"891-901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Phase I\/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-9353","authenticated-orcid":false,"given":"Wolfgang","family":"Lilleby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav","family":"Gaudernack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paal F.","family":"Brunsvig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ljiljana","family":"Vlatkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut H\u00e5kon","family":"Hole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else Marit","family":"Inderberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,8]]},"reference":[{"key":"1994_CR1","first-page":"2798","volume":"126","author":"W Lilleby","year":"2006","unstructured":"Lilleby W, Hernes E, W\u00e6hre H, Raabe N, Foss\u00e5 SD (2006) Treatment of hormone-resistant prostate cancer. Tidsskr Nor Laegeforen 126:2798\u20132801","journal-title":"Tidsskr Nor Laegeforen"},{"key":"1994_CR2","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13014-015-0540-3","volume":"10","author":"W Lilleby","year":"2015","unstructured":"Lilleby W, Narang A, Tafjord G, Vlatkovic L, Russnes KM, Stensvold A, Hole KH, Tran PT, Eilertsen K (2015) Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy. Radiat Oncol 10:232\u2013237. doi:\n10.1186\/s13014-015-0540-3","journal-title":"Radiat Oncol"},{"key":"1994_CR3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/13543780902897631","volume":"18","author":"JA Kyte","year":"2009","unstructured":"Kyte JA (2009) Cancer vaccination with telomerase peptide GV1001. Expert Opin Investig Drugs 18:687\u2013694","journal-title":"Expert Opin Investig Drugs"},{"key":"1994_CR4","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.4049\/jimmunol.174.6.3798","volume":"174","author":"Z Su","year":"2005","unstructured":"Su Z, Dannull J, Yang BK et al (2005) Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174:3798\u20133807","journal-title":"J Immunol"},{"key":"1994_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrclinonc.2016.67","volume":"14","author":"M Zanetti","year":"2017","unstructured":"Zanetti M (2017) A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nat Rev Clin Oncol 14:115\u2013128. doi:\n10.1038\/nrclinonc.2016.67","journal-title":"Nat Rev Clin Oncol"},{"key":"1994_CR6","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1007\/s12035-015-9170-x","volume":"53","author":"J Li","year":"2016","unstructured":"Li J, Li H, Liu J, Feng B, Feng M, Lv B, Cheng S, Yang X (2016) The clinical implications of human telomerase reverse transcriptase expression in grade and prognosis of gliomas: a systematic review and meta-analysis. Mol Neurobiol 53:2887\u20132893. doi:\n10.1007\/s12035-015-9170-x","journal-title":"Mol Neurobiol"},{"key":"1994_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/PAT.0b013e3283511cd5","volume":"44","author":"JS Shin","year":"2012","unstructured":"Shin JS, Foo T, Hong A, Zhang M, Lum T, Solomon MJ, Lee CS (2012) Telomerase expression as a predictive marker of radiotherapy response in rectal cancer. Pathology 44:209\u2013215. doi:\n10.1097\/PAT.0b013e3283511cd5","journal-title":"Pathology"},{"key":"1994_CR8","doi-asserted-by":"publisher","first-page":"670","DOI":"10.4161\/onci.20426","volume":"1","author":"EM Inderberg-Suso","year":"2012","unstructured":"Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G (2012) Widespread CD4+ T cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology 1:670\u2013686. doi:\n10.4161\/onci.20426","journal-title":"Oncoimmunology"},{"key":"1994_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. doi:\n10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"1994_CR10","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock T et al (2008) Design and endpoints of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone. J Clin Oncol 26:1148\u20131159","journal-title":"J Clin Oncol"},{"key":"1994_CR11","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/sj.cgt.7700961","volume":"13","author":"JA Kyte","year":"2006","unstructured":"Kyte JA, Mu L, Aamdal S et al (2006) Phase I\/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 13:905\u2013918","journal-title":"Cancer Gene Ther"},{"key":"1994_CR12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/sj.cgt.7700837","volume":"12","author":"JA Kyte","year":"2005","unstructured":"Kyte JA, Kvalheim G, Aamdal S, Saeboe-Larssen S, Gaudernack G (2005) Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. Cancer Gene Ther 12:579\u2013591","journal-title":"Cancer Gene Ther"},{"key":"1994_CR13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00262-011-0991-9","volume":"60","author":"EM Suso","year":"2011","unstructured":"Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, Gaudernack G (2011) hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunother 60:809\u2013818","journal-title":"Cancer Immunol Immunother"},{"key":"1994_CR14","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1002\/eji.201141452","volume":"41","author":"J Charo","year":"2011","unstructured":"Charo J, Perez C, Buschow C, Jukica A, Czeh M, Blankenstein T (2011) Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors. Eur J Immunol 41:3187\u20133197","journal-title":"Eur J Immunol"},{"key":"1994_CR15","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1158\/1078-0432.CCR-15-2594","volume":"22","author":"MI Poelgeest van","year":"2016","unstructured":"van Poelgeest MI, Welters MJ, Vermeij R et al (2016) Vaccination against oncoproteins of HPV16 for noninvasive vulvar\/vaginal lesions: lesion clearance is related to the strength of the T cell response. Clin Cancer Res 22:2342\u20132350. doi:\n10.1158\/1078-0432.CCR-15-2594","journal-title":"Clin Cancer Res"},{"key":"1994_CR16","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00262-006-0145-7","volume":"55","author":"PF Brunsvig","year":"2006","unstructured":"Brunsvig PF, Aamdal S, Gjertsen MK et al (2006) Telomerase peptide vaccination: a phase I\/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 55:1553\u20131564","journal-title":"Cancer Immunol Immunother"},{"key":"1994_CR17","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI et al (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15:700\u2013712. doi:\n10.1016\/S1470-2045(14)70189-5","journal-title":"Lancet Oncol"},{"key":"1994_CR18","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.urology.2013.01.061","volume":"81","author":"PF Schellhammer","year":"2013","unstructured":"Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW (2013) Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology 81:1297\u20131302. doi:\n10.1016\/j.urology.2013.01.061","journal-title":"Urology"},{"key":"1994_CR19","doi-asserted-by":"crossref","unstructured":"Nemunaitis J, Susan N, Rabinowe ND et al (1991) Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. \nhttp:\/\/products.sanofi.us\/Leukine\/Leukine.html\n\n. Accessed 20 Feb 2017","DOI":"10.1056\/NEJM199106203242504"},{"key":"1994_CR20","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1159\/000442269","volume":"38","author":"A Heidenreich","year":"2015","unstructured":"Heidenreich A (2015) New developments in the management of prostate cancer. Oncol Res Treat 38:628. doi:\n10.1159\/000442269","journal-title":"Oncol Res Treat"},{"key":"1994_CR21","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ijrobp.2015.10.056","volume":"94","author":"AK Narang","year":"2016","unstructured":"Narang AK, Gergis C, Robertson SP et al (2016) Very high-risk localized prostate cancer: outcomes following definitive radiation. Int J Radiat Oncol Biol Phys 94:254\u2013262. doi:\n10.1016\/j.ijrobp.2015.10.056","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1994_CR22","doi-asserted-by":"publisher","first-page":"14565","DOI":"10.1073\/pnas.251140998","volume":"98","author":"M Mercader","year":"2001","unstructured":"Mercader M, Bodner BK, Moser MT et al. (2001) T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci 98:14565\u201314570. doi:\n10.1073\/pnas.251140998","journal-title":"Proc Natl Acad Sci"},{"key":"1994_CR23","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Can Res 15:7412\u20137420","journal-title":"Clin Can Res"},{"key":"1994_CR24","doi-asserted-by":"publisher","unstructured":"Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:737\u2013746. doi:\n10.1056\/NEJMoa1503747","DOI":"10.1056\/NEJMoa1503747"},{"key":"1994_CR25","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1158\/1078-0432.CCR-11-1385","volume":"17","author":"PF Brunsvig","year":"2011","unstructured":"Brunsvig PF, Kyte JA, Kersten C, Sundstrom S, Moller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S (2011) Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I\/II trial. Clin Can Res 17:6847\u20136857","journal-title":"Clin Can Res"},{"key":"1994_CR26","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/pros.20794","volume":"68","author":"TJ Harris","year":"2008","unstructured":"Harris TJ, Hipkiss EL, Borzillary S et al (2008) Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate 68:1319\u20131329. doi:\n10.1002\/pros.20794","journal-title":"Prostate"},{"key":"1994_CR27","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-06-1772","volume":"13","author":"NJ Nesslinger","year":"2007","unstructured":"Nesslinger NJ, Sahota RA, Stone B et al (2007) Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 13:1493\u20131502","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-017-1994-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-1994-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-1994-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T07:18:26Z","timestamp":1498634306000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-017-1994-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,8]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["1994"],"URL":"https:\/\/doi.org\/10.1007\/s00262-017-1994-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,8]]}}}